for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Mitsubishi Tanabe Pharma Corp

4508.T

Latest Trade

1,232.00JPY

Change

-21.00(-1.68%)

Volume

1,276,200

Today's Range

1,225.00

 - 

1,256.00

52 Week Range

1,128.00

 - 

1,796.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
1,253.00
Open
1,254.00
Volume
1,276,200
3M AVG Volume
23.02
Today's High
1,256.00
Today's Low
1,225.00
52 Week High
1,796.00
52 Week Low
1,128.00
Shares Out (MIL)
560.78
Market Cap (MIL)
709,632.30
Forward P/E
47.86
Dividend (Yield %)
4.43

Next Event

Q2 2020 Mitsubishi Tanabe Pharma Corp Earnings Release

Latest Developments

More

Viela Bio Enters Strategic Collaboration With Mitsubishi Tanabe Pharma

EU Medicines Agency Says Application For Initial Marketing Authorization For Mitsubishi Tanabe Pharma's Radicava (Edaravone) Has Been Withdrawn

Tanabe Research Says U.S. FDA Accepted Its IND Application For TR1801-ADC

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Mitsubishi Tanabe Pharma Corp

Mitsubishi Tanabe Pharma Corporation is a Japan-based company mainly engaged in the manufacture and sale of pharmaceutical products. The medical supplies business is engaged in the research, development, manufacture and sale of ethical pharmaceutical and non-prescription drugs. The Company’s subsidiaries receive raw materials from the company and sell products locally.

Industry

Major Drugs

Contact Info

3-2-10, Dosho-machi, Chuo-ku

+81.6.62055085

https://www.mt-pharma.co.jp/

Executive Leadership

Masayuki Mitsuka

Executive President, President, Representative Director

Megumi Ohtaki

Chief Compliance Officer, Executive Officer, Director of Pharmaceutical Affairs

Takashi Kobayashi

Senior Managing Executive Officer, Representative Director

Yoshiaki Ishizaki

Managing Executive Officer, Director

Seiichi Murakami

Managing Executive Officer, Director

Key Stats

3.11 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, JPY)

2017

0.4K

2018

0.4K

2019

0.4K

2020(E)

0.4K
EPS (JPY)

2017

127.030

2018

103.350

2019

66.640

2020(E)

11.613
Price To Earnings (TTM)
23.40
Price To Sales (TTM)
1.70
Price To Book (MRQ)
0.80
Price To Cash Flow (TTM)
19.11
Total Debt To Equity (MRQ)
0.02
LT Debt To Equity (MRQ)
0.02
Return on Investment (TTM)
2.61
Return on Equity (TTM)
2.38

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up